Biogen Tecfidera US win: Broad, clean label; price pending
This article was originally published in Scrip
Executive Summary
The much-anticipated US approval for Biogen Idec's new multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate), previously known as BG-12, came not only one day ahead of its 28 March Prescription Drug User Fee Act action date, but with broad, clean labeling – generating a sigh of relief on Wall Street, as shares of the firm climbed 3% in the short half-hour between the US FDA's notice and the bell.